<SEC-DOCUMENT>0000950103-21-016985.txt : 20211101
<SEC-HEADER>0000950103-21-016985.hdr.sgml : 20211101
<ACCEPTANCE-DATETIME>20211101082527
ACCESSION NUMBER:		0000950103-21-016985
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211101
FILED AS OF DATE:		20211101
DATE AS OF CHANGE:		20211101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		211365394

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp160833_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November 1, 2021</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39363</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMATICS N.V.</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paul-Ehrlich-Stra&szlig;e 15</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>72076 T&uuml;bingen, Federal Republic of Germany</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P>
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9744;</P>
</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 1, 2021, Immatics N.V. (the &ldquo;Company&rdquo;)
issued a press release announcing its presentations at the Society for Immunotherapy of Cancer&rsquo;s 36th Annual Meeting. A copy the
press release is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 8pt"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%; font-size: 8pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 10pt">Press  release dated November 1, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMATICS N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: November 1, 2021</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp160833_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PRESS RELEASE</B></FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; background-color: white"><B>Immatics
</B></FONT><B><FONT STYLE="font-size: 12pt">to Present Update on Lead ACTengine<SUP>&reg;</SUP> Program IMA203 Targeting PRAME at the
Society for Immunotherapy of Cancer&rsquo;s 36th Annual Meeting </FONT></B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Houston,
Texas</B></FONT><B> <FONT STYLE="font-size: 10pt">and Tuebingen, Germany<FONT STYLE="background-color: white">, </FONT>November 1<FONT STYLE="background-color: white">,
2021</FONT></FONT></B> <FONT STYLE="font-size: 10pt">&ndash; <FONT STYLE="color: Blue"><U>Immatics N.V</U>.</FONT> (NASDAQ: IMTX, &ldquo;Immatics&rdquo;),
a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today
announced that the company will provide an update on its ACTengine<SUP>&reg;</SUP> IMA203 trial in a late-breaking oral presentation
as well as an update on Immatics&rsquo; next-generation CD8<FONT STYLE="font-family: Symbol">ab</FONT> TCR-T approach at the 36<SUP>th
</SUP>Annual Meeting of the Society for Immunotherapy of Cancer&rsquo;s (SITC). The conference will take place, both in person and virtually,
from November 10 - 14, 2021.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Today, SITC announced
presentation titles and timings as follows:</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>IMA203 Phase
1a Clinical Data Update:</U></B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Presentation
Title: </B>Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers
at low doses &ndash; clinical update on the ACTengine<SUP>&reg;</SUP> IMA203 trial</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Speaker: </B><FONT STYLE="background-color: white">Martin
Wermke, MD, </FONT>Coordinating Investigator of Immatics ACTengine<SUP>&reg;</SUP> trials in Germany and Head of the Early Clinical Trial
Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Abstract Number:
</B>959</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Category</B>:
Late-breaking oral abstract presentation</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Date &amp; Time: </B>Saturday, November
13, 2021; 12:00 - 12:15 pm EDT</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Next-generation
CD8<FONT STYLE="font-family: Symbol">ab</FONT> TCR-T approach - Preclinical Data Update:</U></B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Presentation Title:</B> Improved anti-tumor
activity of next-generation TCR-engineered T cells through CD8 co-expression</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Speaker:</B> Mamta Kalra, PhD, Director
CMC (Process Development) at Immatics<BR>
<B>Abstract Number:</B> 163</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>Category:</B> Poster abstract presentation<BR>
<B>Date &amp; Time: </B>Friday, November 12, 2021; Poster Hall Hours: 7 am&ndash;8:30 pm EDT</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 11pt"><FONT STYLE="font-size: 9pt">Immatics Press Release November 1, 2021</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 9pt"><FONT STYLE="font-size: 9pt">1 | <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">All posters presented at the poster hall
will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">- END -<BR>
<BR></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>About ACTengine<SUP>&reg;
</SUP>IMA200 programs</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Each of the product
candidates of the IMA200 programs is based on Immatics&rsquo; proprietary ACTengine<SUP>&reg;</SUP> approach in which the patient&rsquo;s
own T cells are genetically engineered to express a novel, proprietary TCR directed against a defined cancer target. The modified T cells
are then reinfused into the patient to attack the tumor, an approach also known as TCR-T. ACTengine<SUP>&reg;</SUP> programs IMA201,
IMA202 and IMA203 are currently in clinical development for the treatment of solid tumor indications, both in the US and in Germany.
IMA204 is currently in pre-clinical development. All ACTengine<SUP>&reg;</SUP> product candidates can be rapidly manufactured utilizing
a proprietary manufacturing process designed to enhance T cell engraftment and persistence <I>in vivo.</I></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The ACTengine<SUP>&reg;
</SUP>T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth.
The ACTengine<SUP>&reg;</SUP> IMA200 Programs are co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT).</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt"><FONT STYLE="font-size: 10pt"><B>About Immatics</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics combines
the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies
and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the
power of T cells and to unlocking new avenues for patients in their fight against cancer.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For regular updates
about Immatics, visit <FONT STYLE="color: Blue"><U>www.immatics.com</U></FONT>. You can also follow us on <FONT STYLE="color: Blue"><U>Twitter
</U></FONT>and <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><B>For
more information, please contact:</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>For
    Media Inquiries</B></FONT></TD>
    <TD STYLE="width: 49%; font-size: 11pt"><FONT STYLE="font-size: 10pt"><B>Investor Relations Contact</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Jacob Verghese
    or Stephanie May</FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">Eric Goldstein or John Mullaly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Trophic
    Communications</FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">LifeSci Advisors</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Phone:
    +49 89 2388 7731 </FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">Phone: +1 646 791 9729 or +1 617-429-3548</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 11pt"><FONT STYLE="font-size: 9pt">Immatics Press Release November 1, 2021</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 9pt"><FONT STYLE="font-size: 9pt">1 | <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 12pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: Blue"><U>immatics@trophic.eu</U></FONT></TD>
    <TD STYLE="width: 49%; font-size: 11pt"><FONT STYLE="font-size: 10pt; color: Blue"><U>egoldstein@lifesciadvisors.com</U></FONT> <FONT STYLE="font-size: 10pt">or
    <FONT STYLE="color: Blue"><U>jmullaly@lifesciadvisors.com</U></FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Immatics N.V.</B></FONT></TD>
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Anja Heuer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Jordan Silverstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director, Corporate Communications</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Head of Strategy</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phone: +49 89 540415-606 </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Phone: +1 281 810 7545</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>media@immatics.com</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: Blue"><U>InvestorRelations@immatics.com</U></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 78%; font-size: 11pt"><FONT STYLE="font-size: 9pt">Immatics Press Release November 1, 2021</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 9pt"><FONT STYLE="font-size: 9pt">1 | <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( ,(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH ****  G R>E<ROCO19O$5OHMK(]S-*Y0RQC]VI )Q
MN[].V:I>/?&$WAG[!%:Q1RRSN7D23H8QP1[9)Z^U8/AG3?"^M^)K75]&N)+*
MX@)FFTUTX'&,J>PR1TR/85A.J^;DCN>QA<OC]7>)Q"?*T^5K:Z[]5KMT[V-&
M3XJ65GJ]S8WVF7$0@F:)I8W#_=.,XX-=KIVIV>KV27EA<)/ _1E/0^A'8^QK
MPGQ=H6KZ=K%Y?7]H4@N;AY$F0[HSN8D#(Z'ZXJQX U^71/$L$1<_8[QQ#,A/
M&3PK?4']":PAB)*?+,];$Y'AZN%]OA7[R5][IZ:^CW/=W=(T9Y&"HHR68X %
M<O>^.K""0I;02W./XP=JGZ9Y_2L_QSJDC7$>EQ,1&%$DH'\1/0?3O6!H^AW.
MN2R);LB)&/GD?H,]!QWK.OBJGM/94EJ?!UL1/GY*>YV%MXXM&=%O+.>U5QE7
M(W*1Z^N/H*Z:*:.>)98G5XW&593D$5Q&OZ5K&H:E9Z>D&ZVAC58Y]OR] &9C
MVZ=*L^'UNO#^N?V)=2K)%<1^;$5Z!N<_3.#^5:4Z]13Y:BNMKVMJ7"K-2Y9[
M;7\SJKN\M[&V>XNIEBB7JS&N3N?B)9I(5MK&:91_$S!,_AS7/>,M7DU'6I+8
M,?L]JQ15[%OXF_I^%<[7TV&P$'!2J:MGCXS-JBJ.%'1+KW/3=-\=Z;>RK%<)
M)9NQP&D(*?F.GXUU(((R#D&O":]#\ ZO)<VLVFS,6:W :(GKL/&/P/\ .L\9
M@HTX^TIF^79G.K/V57=[,[.BBBO+/<"BBB@ HHHH **** "BBB@ HHHH ***
M* /(_B_;R+JVF7)!\IX&C!_V@V?Y&LSX>=/$13_6_P!F/LQU[_\ UJ]6\3^'
M;?Q-HSV,S>7(#OAEQDQN.A^G8CT->6^'++4?!GC2"/5[5X[6X#6TDP&8F#=#
MNZ8R!UYKAJ0<:W/T9]A@,7"OEDL.G[\5MW2:EIWV:,GPWXPO-%06ER#?:3(-
MLMI-\PV]]N>GTZ']:T=4\+10:YHU[HC&;2=3N(S;MU,3;@2A^@!Z^A':L/6?
M#]YIGB.YTB*WEF='_<B-"Q=#RIX]OU!KUKX>Z!J6C:&T6JA 'E\Z"W(#-"2.
M23V)]!TY]:SI0E-\DNGX';F&)HX6"Q=!J\UJOYDUH[=UW[73*NLZA)H?C2:\
M^SK,)85VACCC &0?JM6M"U;5!#>:A<6:_P!G"-I$$484D@]%QR>_)]*U_$F@
MKK5HIC(2ZBR8V/0CNI]JYX>([W1=(&F76FNEQ&AC21CA".@/O^%$U*E5;DVH
MZM>K/S22=.HW)V6Z]3)UOQ#<:M?1SQ[[=(A^[57.<]<G'>I/#CW.H>*[26:5
MY9%)9G<Y. I_QK(M;2XO)!%:P23.>,(N?S/:O1?#'A[^QH&FG*M=RC#8Y"+_
M '1_6N;#PJ5JO,]KW9A1C.K4YGMN>;ZU"UOKE_')PPG<_@3D?H:9<:5J%I;)
M<7-G-%"_W79<#V^GXUW_ (L\,2:C*FI6"J;N/&^-NDH'3\?YBLCQ)XL-[I+Z
M<^G3VUQ)CS?.& N"#QZ]*^YI8F5105-7[^1Y-?!1I2J.J[=8Z:/^O^"<977_
M  \A=M8NIAG8D&TGW+#'\C7.:?I-]JLPCL[9Y,]7QA%^IZ5ZKX?T2+0M.%NK
M;Y6.Z63'WF_P%&/KQC3<+ZL>586<ZRJV]U&K1117@GU045Y5XO\ %NNZ;\8?
M#^AV=^8M-NO(\Z#RU._<[ \D9' '0UO_ !'^($/@;2XO*B6XU.ZR+>%C\H Z
MNV.<#(X[DT =M17A]MI'QEUZW&I/K*:?O&Z.V=UB..WRA#C_ ($<^M,L_BWX
ME\(7-WI'C73&N+R*(M!(@5&=OX<D?*4/]X=/0T >YT5X5I\GQ;\>0?VK::A%
MI-A(28%!$2L/]GY68CW/6I+7Q_XS^'^N0:=XZC^UZ?-]V[4 L!W964 ,!GE2
M,_U /<:*PO$_BS3_  OX9DURY;S8=J^2D9YF9ONJI]^N?3)KR:PN_BQ\0(SJ
M>GWL6D::Y/DX(C5A_LG:68>YP/2@#W:BO#$\<>.OAUJ]O:^,XO[1TV8X6X0*
M6QW*. ,D?W6 --A\4_$;XDWUPWAC9I6DQ/L$I(7\&<@DMC&0HP* /=:*\)O-
M<^)_PVEBN]<ECUC2F<*[%@XR>V\*&0^A((KV+0]?L/$&@6^M6<O^B31[\OP4
MQ]X-Z$$$'Z4 :E(0&!! (/8UXOK'Q1\1>*=<DT3X>V7F*GWKUD!+#IN&[Y47
MT+<GL*:?#'QF@3[4GB2&68<^1YZG\,%-M 'M6!G.!GUJMJ=V=/TF\O50.UO
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M^"*** /3Z\S^+W@O6O&$6C+HT,,AM9)6E\V4)@,%QCUZ&BB@#TJ-2L2*>H4
MUQ?Q3\-:GXJ\'_V;I,<;W/VF.3$DFP;1G//XT44 <GXR^'GB+6OAWX6T:R@M
MVO=.C"W"M.%4'R]O![\UZU8Q/!I]M#( 'CB56P>X !HHH YKXE:!J'B;P1=:
M7IB1O=221,JR/L&%<$\_05=\#:3=Z%X)TG2[]46ZMH-DBHVX Y/0]Z** +?B
M:QGU3PMJMA:JK7%S:2Q1AC@%F4@9/;DUS7PI\+ZGX4\(S:=K$427#W;RA8Y
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3,#HJCLHR?J3110!V=%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
